Search results
Pets at Home kicks off £25m share buyback programme
ShareCast· 1 day agoPets at Home Group announced the start of a £25m share buyback programme on Monday, after committing to one in its preliminary results.
Merck shares plunge on failure of cancer drug trial
ShareCast· 13 hours agoShares of German chemical and pharmaceutical firm Merck were falling sharply on Tuesday, after it announced that a trial for its head and neck cancer...
EU calls Microsoft's bundling of Teams 'abusive'
ShareCast· 13 hours agoThe European Union (EU) accused Microsoft of violating competition regulations on Tuesday, through the “abusive” bundling of its Teams and Office...
Director dealings: Aviva non-exec invests, Britvic director covers share award costs
ShareCast· 10 hours agoAmong the director dealings disclosed to market on Tuesday, Aviva announced that T Neil Morrison, a...
Proton Motor Power gets follow-up order from Deutsche Bahn
ShareCast· 11 hours agoProton Motor Power Systems, a designer and producer of zero-carbon fuel cells and fuel cell electric...
Sound Energy demobilises Tendrara workover rig
ShareCast· 15 hours agoSound Energy has announced the successful completion and demobilisation of the Star Valley Rig 101 on Tuesday, following planned workover operations on...
Orchard Funding lifts expectations amid strong premium finance market
ShareCast· 15 hours agoInsurance premium finance and professions funding specialist Orchard Funding Group reported a robust...
Gear4music revenue falls, profit rises as expected
ShareCast· 17 hours agoOnline musical instrument and equipment retailer Gear4music reported final results in line with market forecasts on Tuesday, with revenue down 5%...
Wynnstay reports weaker first half amid challenging market
ShareCast· 17 hours agoWynnstay Group reported a set of interim results impacted by challenging trading conditions on...
AstraZeneca posts mixed results from recent Imfinzi trials
ShareCast· 18 hours agoAstraZeneca announced contrasting results from two phase three trials involving its immunotherapy...